Tohoku J. Exp. Med., 2013 Feb, 229 (2) , 107-114. © 2013 Tohoku University Medical Press Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin with high antitumor efficacy (Fukuoka et al. 1992; Shimada et al. 1993) . It inhibits topoisomerase I (Kawato et al. 1991) and is used for treatment of lung, gastric, colon, cervical, and ovarian cancers in Japan. However, CPT-11 often causes adverse events such as myelosuppression and diarrhea (Cersosimo 1998) . CPT-11 is metabolized to the active form, SN-38, by carboxylesterase, and is then converted to the inactive form, , by uridine diphosphate glucuronosyltransferase (UGT) 1A enzymes (Dodds et al. 1998) . It is known that adverse events are associated with serum concentration of SN-38 and UGT1A enzyme activities (Gupta et al. 1994) . The UGT1A isozymes include UGT1A1, UGT1A7 and UGT1A9 (Ando et al. 2000; Innocenti et al. 2004; Carlini et al. 2005) , and the genetic variations present in their genes affect the enzyme activities. As shown in Table 1 , variant alleles, which give rise to the altered enzymatic activities, are UGT1A1*6, UGT1A1*28, UGT1A7*2, UGT1A7*3, and UGT1A9*22, respectively, reported in East Asians (Yamanaka et al. 2004; Araki et al. 2006; Han et al. 2006) . Each number with an asterisk identifies a variant allele. For example, UGT1A1*28 represents a tandem repeat polymorphism in the TATA box and is considered as a major predictive pharmacogenetic marker of severe hematological toxicity in Caucasians (Ando et al. 2000) . The United States Food and Drug Administration recommends genetic analysis of this polymorphism prior to CPT-11 administration, and reduction in the starting CPT-11 dosage by at least one level in patients who are homozygous for the UGT1A1*28 allele (Refer to NDA 20-571/S-024/S-027/ S-028). UGT1A1*6 is also a causative factor for decreased UGT1A1 expression (Aono et al. 1993; Sugatani et al. 2002) , mainly found in East Asians (Sai et al. 2004; Kaniwa et al. 2005) . Among polymorphisms of UGT1A7 gene, *2 and *3 but not *4 are found in East Asians (Ando et al. 2002) . Villeneuve et al. (2003) reported that UGT1A7*2 was associated with higher enzyme activity than UGT1A7*1, and that UGT1A7*3-associated enzyme activity was 41% lower than that of UGT1A7*1. Among polymorphisms of UGT1A9 gene, UGT1A9*22 is the most often found in Asian populations (Yamanaka et al. 2004 ). This polymorphism is associated with increased enzyme expression levels that cause high glucuronidation rate of SN-38 (Han et al. 2009) .
In this study, to elucidate the association of polymorphisms of three UGT1A isozymes genes with CPT-11-derived severe adverse events, we determined the UGT1A1*6, UGT1A1*28, UGT1A7*2, UGT1A7*3, UGT1A7*4, and UGT1A9*22 alleles in 45 cancer patients receiving CPT-11-based chemotherapy. Finally, we found t h a t p a t i e n t s w i t h o n e o r m o r e g e n o t y p e s o f UGT1A1*6/*28, UGT1A7*3/*3, and UGT1A9*1/*1 suffer from severe adverse events leading to either the discontinuation of chemotherapy or the decrease of CPT-11 administration dose.
Materials and Methods

Patients and CPT-11-based chemotherapy
This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the Ethics Committee of the Shizuoka General Hospital and University of Shizuoka, Shizuoka, Japan. Forty-five Japanese patients receiving CPT-11-based chemotherapy, who were hospitalized at the Shizuoka General Hospital from December 2007 to December 2008, were enrolled in this study. Written informed consent was obtained from each patient after a detailed briefing of the study purposes and protocols. Four types of CPT-11 regimens were used for lung cancer, including CPT-11 mono-therapy (60 mg/m 2 ) (see Table 3 ). Folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) (100 mg/m 2 ) or FOLFIRI/bevacizumab (100 mg/m 2 ) were used for colon cancer, and for stomach cancer, S-1 (Tegafur/Gimeracil/Oteracil potassium compound)/CPT-11 or biweekly cisplatin (CDDP)/CPT-11 (30 mg/m 2 ) was used. The doses used were less than the maximum recommended dosages [lung: CPT-11 mono-therapy, 100 mg/m 2 (Negoro et al. 2003) ; colon: FOLFIRI, 180 mg/m 2 (Douillard et al. 2000) and FOLFIRI/bevacizumab, 180 mg/m 2 (Fuchs et al. 2007 ); and stomach: biweekly CDDP/CPT-11, 70 mg/m 2 (Boku et al. 1999) ]. The dosing regimens were not determined by patient's UGT1A1 genotypes since they have never had pharmacogenetic testing. No restriction was put on whatever the previous chemotherapy regimens were. No standard was set to reduce the dose of second-course CPT-11 in patients who suffered neutropenia in the first course. Second course therapy was started after their neutrophil levels recovered to the normal levels. In this study, therapeutic intervention defined as either the discontinuation of chemotherapy or the decreased change of the administration dose, caused by the severe adverse events. Adverse events were assessed according to the Common Terminology Criteria for Adverse events v 4.0.
Genotyping procedures
Peripheral blood (5 mL) was obtained from patients using EDTA-2Na Venoject II tubes (Terumo, Tokyo, Japan). Leukocyte genomic DNA was directly extracted from blood specimens using QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's instruction. The UGT1A9*22 genotype was determined by using a direct sequencing method, and UGT1A7*2, UGT1A7*3, and UGT1A7*4 genotypes were analyzed by using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) according to the procedures reported previously (van der Logt et al. 2004; Yamanaka et al. 2004) . The UGT1A1*6 and UGT1A1*28 genotypes were simultaneously analyzed by using a direct sequencing method. Genomic DNA was amplified by PCR using the primer set (forward: 5′-TTA ACT TGG TGT ATC GAT TGG T-3′ and reverse: 5′-TTG TTG TGC AGT AAG TGG GA-3′), and the polymorphic regions were determined by direct sequencing. Sequencing was performed using the ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and Big Dye Terminator Cycle Sequencing Kit v 1.1 (Applied Biosystems) according to the manufacturer's instruction.
Statistical analyses
Genotyping data for deviation from the Hardy-Weinberg equilibrium was analyzed by the chi-square test. Both Fisher's exact test and chi-square test were used to compare categorical variables (age, sex, tumor types, regimens, and genetic factors) between patients with or without therapeutic intervention of CPT-11-based chemotherapy. Furthermore, logistic regression models were utilized to esti- lung ： biweekly CBDCA/CPT-11 3 (6.7) lung ： CPT-11 mono-therapy 2 (4.4) 
Results
Characteristics of enrolled patients
The characteristics of the enrolled patients are listed in Table 2 . As for the type of cancer, lung cancer (28/45: 62.2%) was dominant. As for regimens of CPT-11-based chemotherapy, four regimens were applied to lung cancer, and two regimens were applied to colon or stomach cancer. Severe adverse events such as the grade 3 and 4 neutropenia were observed in 12 patients (26.7%). As for the UGT1A1 alleles, the numbers of patients having the *1/*1, *1/*6, *1/*28, and *6/*28 genotypes were 26, 9, 6, and 4, respectively. No patient who had the homozygous *6/*6 or *28/*28 alleles was found. As for the UGT1A7 alleles, the numbers of patients having *1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 genotypes were 20, 6, 13, 3, and 3, respectively. There was no patient who had the UGT1A7*4 allele. As for the UGT1A9 alleles, the numbers of patients with *1/*1, *1/*22, and *22/*22 genotypes were 5, 20, and 20, respectively. One patient who carries the A(T) 10 AT/A(T) 11 AT genotype was included in the *22/*22 group. The genotype distributions of these genes were in accordance with the Hardy-Weinberg equilibrium (p > 0.05). Table 3 illustrates the association between potential factors (age, sex, tumor types, regimens, and genetic factors) and the therapeutic intervention. Ten patients (22.2%) suffered from adverse events that lead to the therapeutic intervention during the course of chemotherapy. By univariate analysis, no significant association was found between the therapeutic intervention and age, sex, tumor types, regimens, or genetic polymorphisms of UGT1A1, UGT1A7, or UGT1A9. On the other hand, the significant association ( p = 0.008) was found between combined genotypes of UGT1A1*6/*28, 1A7*3/*3, and 1A9*1/*1 and the therapeutic intervention. Moreover, multivariate analysis revealed that UGT1A genotype combination was significantly correlated with the therapeutic intervention (p = 0.014; Table 4 ). No significant difference was observed between the therapeutic intervention and the other factors (age, sex, tumor types, regimens, and polymorphisms of UGT1A1, UGT1A7, or UGT1A9).
Potential factors associated with therapeutic intervention
Genotypes of UGT1A isozymes associated with therapeutic intervention
The occurrences of adverse events leading to therapeutic intervention in all enrolled patients are summarized in Table 5 . Four patients (Nos. 1, 2, 6, and 11) with the combined genotype of *1/*1-*1/*1-*22/*22 underwent the therapeutic intervention. Especially, two patients (Nos. 1 and 2) showed the severe neutropenia (grade 4). Two patients (Nos. 23 and 28) having the wild/mutant heterozygote also suffered from severe adverse events. In these patients, the reason why the adverse events occurred is unclear, but the factors other than genetic factors may be responsible for the toxicity. As for the patients having one or more genotypes of UGT1A1*6/*28, UGT1A7*3/*3, and UGT1A9*1/*1, four (67%) out of six patients suffered the therapeutic intervention. The detailed descriptions of the occurrence of adverse events leading to the therapeutic intervention in these six patients are shown in Table 6 . From these results, genotypes of three UGT1A isozymes (UGT1A1*6/*28, UGT1A7*3/*3, and UGT1A9*1/*1) may be a useful marker for prediction of adverse events caused by CPT-11.
Discussion
In this study, we found that one or more genotypes of three UGT1A isozymes may be useful for predicting the adverse events caused by CPT-11-based chemotherapy. In general, UGT1A1*28 is the most important allele for avoiding the severe adverse events such as neutropenia and/or diarrhea caused by SN-38, the active form of CPT-11 (Toffoli et al. 2003) . Pharmacogenetic testing of this allele is recommended prior to treat cancer patients with CPT-11 in U.S. (Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. 2009). On the other hand, in Oriental population, the frequency of the UGT1A1*28 homozygote is not so high as compared to the Caucasian population (Lampe et al. 1999) . The frequency of UGT1A1*6, which is also the defective allele, is high in the Oriental population. Therefore, a pharmacogenetic study about CPT-11 in Japan focused on the UGT1A1*6 and UGT1A1*28 alleles (Araki et al. 2006 ). In fact, there are quite a few patients who have wild-type alleles of UGT1A1*6 and UGT1A1*28 suffered from severe adverse events. The factors other than these alleles affecting the efficacy of CPT-11 were investigated in this study. Univariate and multivariate analysis have revealed that the one or more of the UGT1A1*6/*28, UGT1A7*3/*3 and UGT1A9*1/*1 genotypes are the risk factors for the adverse events by CPT-11 (Tables 3 and 4 ). Four out of six patients with one or more above genotypes showed adverse events leading the therapeutic intervention (Tables 5 and 6 ). A previous study has shown that UGT1A7*3/*3 caused the low enzymatic activity for glucuronization of SN-38 (Gagné et al. 2002) . As for UGT1A9, UGT1A9*22 allele is associated with the higher enzymatic activity than the UGT1A9*1 wild-type allele (Yamanaka et al. 2004) . Since the patients (40/45) who are the homozygous or heterozygous for UGT1A9*22 allele were dominant, the patients with the UGT1A9*1 wild-type allele may be considered as a low enzyme activity group. On the other hand, the UGT1A9*22 allele may lead to the decrease in the efficacy of CPT-11. Heterozygous for defective UGT1A1*6 and UGT1A1*28 alleles also resulted in low enzymatic activity of UGT1A1 (Minami et al. 2007) . From these observations, not only UGT1A1*6/*28 but also UGT1A7*3/*3 and UGT1A9*1/*1 may affect the total enzymatic activity for glucuronization of SN-38, namely, detoxication of CPT-11. In summary, we revealed that the UGT1A7*3/*3 and UGT1A9*1/*1 genotypes should also be taken into consideration for pharmacogenetic testing of UGT1As in Japanese cancer patients prior to CPT-11-based chemotherapy. Table 6 . Characteristics of six patients having one or more genotypes of UGT1A1 *6/*28, UGT1A7 *3/*3, or UGT1A9 *1/*1.
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